Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy.
J Oncol. 2012;2012:408131. doi: 10.1155/2012/408131. Epub 2012 Aug 14.
Adrenocortical carcinoma (ACC) is a very rare endocrine tumour, with variable prognosis, depending on tumour stage and time of diagnosis. The overall survival is five years from detection. Radical surgery is considered the therapy of choice in the first stages of ACC. However postoperative disease-free survival at 5 years is only around 30% and recurrence rates are frequent. o,p'DDD (ortho-, para'-, dichloro-, diphenyl-, dichloroethane, or mitotane), an adrenolytic drug with significant toxicity and unpredictable therapeutic response, is used in the treatment of ACC. Unfortunately, treatment for this aggressive cancer is still ineffective. Over the past years, the growing interest in ACC has contributed to the development of therapeutic strategies in order to contrast the neoplastic spread. In this paper we discuss the most promising therapies which can be used in this endocrine neoplasia.
肾上腺皮质癌（ACC）是一种非常罕见的内分泌肿瘤，其预后因肿瘤分期和诊断时间而异。从发现到整体生存时间为五年。在 ACC 的早期阶段，根治性手术被认为是首选治疗方法。然而，术后 5 年无病生存率仅为 30%左右，且复发率较高。o,p'DDD（邻位、对位、二氯、二苯基、二氯乙烷或米托坦），一种具有显著毒性和不可预测治疗反应的肾上腺溶解药物，用于治疗 ACC。不幸的是，这种侵袭性癌症的治疗仍然无效。在过去的几年中，人们对 ACC 的日益关注促进了治疗策略的发展，以对抗肿瘤的扩散。在本文中，我们讨论了可用于这种内分泌肿瘤的最有前途的治疗方法。
